These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33257171)

  • 1. Angel or Devil ? - CDK8 as the new drug target.
    Wu D; Zhang Z; Chen X; Yan Y; Liu X
    Eur J Med Chem; 2021 Mar; 213():113043. PubMed ID: 33257171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Philip S; Kumarasiri M; Teo T; Yu M; Wang S
    J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
    Solum E; Hansen TV; Aesoy R; Herfindal L
    Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
    Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
    Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
    Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
    Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
    Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
    Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
    Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
    Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK8 kinase--An emerging target in targeted cancer therapy.
    Rzymski T; Mikula M; Wiklik K; Brzózka K
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1617-29. PubMed ID: 26006748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
    Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
    Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
    J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
    He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediator kinase module and human tumorigenesis.
    Clark AD; Oldenbroek M; Boyer TG
    Crit Rev Biochem Mol Biol; 2015; 50(5):393-426. PubMed ID: 26182352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enriching Anticancer Drug Pipeline with Potential Inhibitors of Cyclin-Dependent Kinase-8 Identified from Natural Products.
    Zehra ; Hussain A; AlAjmi MF; Ishrat R; Hassan MI
    OMICS; 2024 Sep; 28(9):478-488. PubMed ID: 39149808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
    Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
    Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases.
    Liang J; Chen M; Hughes D; Chumanevich AA; Altilia S; Kaza V; Lim CU; Kiaris H; Mythreye K; Pena MM; Broude EV; Roninson IB
    Cancer Res; 2018 Dec; 78(23):6594-6606. PubMed ID: 30185549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Search of Novel CDK8 Inhibitors by Virtual Screening.
    Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.
    Sharko AC; Lim CU; McDermott MSJ; Hennes C; Philavong KP; Aiken T; Tatarskiy VV; Roninson IB; Broude EV
    Cells; 2021 Jan; 10(1):. PubMed ID: 33445730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.